Ad-hoc disclosure 📈 Stocks 🌍 Sweden

Enorama Pharma to Repay Loans via 0.4 SEK Share Issue to DS Global

Enorama Pharma will settle debt with DS Global via a directed share issue at 0.4 SEK per share to restore equity and avoid default, resulting in significant dilution for existing shareholders.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 1 Bearish, 0 Neutral. Strongest signal: ENRAPHA ↓ 7/10 (75% confidence).

📊 Affected Assets (1)

ENRAPHA
Bearish 🤖 75%
📅 Short-term 🌍 SE · Explicit

Outstanding loans to main owner DS Global (SEK 20m, SEK 5m and USD 2m + USD 4m facilities) will be repaid via a directed settlement issue at SEK 0.4 per share, implying very large new share issuance of roughly 31m shares. Combined with the previously communicated control balance sheet (negative equity), this means heavy dilution for existing holders, which pressures the share price. The deal does avoid loan defaults and keeps the company funded, which limits an outright insolvency scenario.

Catalysts
  • ▼ Directed settlement issue at SEK 0.4 per share agreed 13 November 2026 to repay all loans under Loan Agreements I-IV including interest
  • ▼ DS Global may exceed 30% ownership through the conversion
Risk Factors
  • ▲ The agreement restores equity and avoids repayment defaults, providing continued funding from the main owner
  • ▲ The conversion is framed as being in the interest of all shareholders and removes uncertainty about loan repayment

🎯 Key Takeaways

  • Enorama Pharma will repay loans from DS Global, including interest, through a directed share issue at 0.4 SEK per share.
  • The debt settlement covers four loan agreements established between May 2022 and February 2026, totaling 25 million SEK and 6 million USD.
  • The conversion may result in DS Global holding more than 30% of the company's shares.
  • The agreement follows the board's February 13, 2026, decision to establish a control balance sheet to address equity concerns.

📝 Executive Summary

Enorama Pharma has entered an agreement to settle outstanding loans with its main owner, DS Global, through a directed share issue. The conversion of debt, including facilities totaling 20 million SEK, 5 million SEK, 2 million USD, and 4 million USD, will be executed at a subscription price of 0.4 SEK per share, potentially pushing DS Global's ownership above 30%.

❓ FAQ

Why is my Enorama Pharma share being diluted?

The company agreed on 13 November 2026 that its loans from main owner DS Global, including interest, will be repaid with newly issued shares at SEK 0.4 per share instead of cash. As DS Global may end up holding more than 30% of the shares, existing owners will be significantly diluted.

Is Enorama Pharma going bankrupt?

The company had set up a control balance sheet, which signals strained equity, but this agreement is described as a step toward restoring shareholders' equity, with the main owner converting all its loans into shares rather than demanding cash repayment.